Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it...

Click to view original post